Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 5,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control/Placebo group Clear all

Conditions: Moderate Risk of CVD
Interventions: Aspirin (Acetylsalicylic acid, BAYE4465), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 55 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 73
States / cities: Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more

Conditions: Intermittent Claudication, Peripheral Artery Disease
Interventions: PLX-PAD Low dose, PLX-PAD high doses, Double Placebo, high dose +Placebo; Biological
Lead sponsor: Pluristem Ltd.; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 15
States / cities: Birmingham, Alabama • Clearwater, Florida • Gainesville, Florida + 12 more

Conditions: Graft-versus-host-disease, Ocular Graft-versus-host Disease
Interventions: Lifitegrast 5% Ophthalmic Solution, Placebo; Drug
Lead sponsor: Richard W Yee, MD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Bellaire, Texas

Conditions: COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Interventions: Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution; Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more

Conditions: Asthma
Interventions: tiotropium-bromide, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Year to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more

Conditions: Coronary Heart Disease
Interventions: Pactimibe, CS-505; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 46
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 43 more

Conditions: Bipolar I Disorder, Alcohol Dependence
Interventions: Quetiapine fumarate, lithium, divalproex; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 38
States / cities: Cerritos, California • San Diego, California • New Haven, Connecticut + 35 more

Conditions: Obesity, Vascular Dementia, Cognitive Impairment
Interventions: Urolithin A, Placebo; Dietary Supplement · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 40 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Cognitive Impairment Associated With Schizophrenia
Interventions: Nicotine patch, MK-4334, Placebo patch, Placebo capsule; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
Interventions: Vixarelimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more

Conditions: Postoperative Pain
Interventions: Methadone, Saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hip Arthropathy, Postoperative Pain, Acute, Pain, Postoperative
Interventions: Active bupivacaine 0.375% PENG block, Placebo normal saline PENG block; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Rett Syndrome
Interventions: Trofinetide, Placebo; Drug · Other
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 5 Years to 20 Years · Female only
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more

Conditions: COVID-19
Interventions: abatacept infusion, Placebo group; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 82
States / cities: Birmingham, Alabama • Tucson, Arizona • Davis, California + 58 more

Conditions: Acne Vulgaris
Interventions: SB204 4%, Vehicle Gel; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 9 Years to 99 Years
Enrollment: 1,307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 55
States / cities: Anaheim, California • Encinitas, California • Fresno, California + 47 more

Conditions: Nutritional Status
Interventions: GSK1325756; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions: MD-7246, Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 80
States / cities: Huntsville, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 65 more

Conditions: Healthy Adults
Interventions: SC Methylnaltrexone (MNTX), IV Methylnaltrexone (MNTX), Oral Paroxetine, SC Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Influenza
Interventions: Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID); Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nausea, Vomiting
Interventions: Glycopyrrolate, Normal Saline; Drug
Lead sponsor: Kokila N Thenuwara; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Premature Infants
Interventions: Vitamin D, Placebo; Dietary Supplement
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Autoimmune Haemolytic Anaemia
Interventions: rilzabrutinib, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 27
States / cities: Phoenix, Arizona • Tucson, Arizona • Duarte, California + 23 more

Conditions: Overactive Bladder
Interventions: LCT-1000TM (Manufacturer: LiteCure); Device
Lead sponsor: Zipper Urogynecology Associates; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: South Miami, Florida

Search by objective public record fields.

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

Urolithin A Supplementation in Middle-aged Adults With Obesity

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Methadone Versus Placebo in Spine Fusion

Pericapsular Nerve Group Block (PENG) for Hip Surgery

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

Higher Dose Intradermal H5 Vaccine

Minimizing Nausea and Vomiting During Spinals for CS

Effect of Vitamin D in Diets of Preterm Infants

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

Painless Laser Therapy for Overactive Bladder

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers